A biotech company spun out of Seattle Children's Hospital has raised $116 million to push forward a novel cell therapy for diffuse intrinsic pontine glioma, a childhood brainstem cancer with no approved drug and a historical death rate near 100 percent. BrainChild Bio's approach takes T cells from patients, genetically engineers them to hunt tumor cells, and reinfuses them directly into the central nervous system rather than through a standard intravenous infusion.
The company's lead candidate, BCB-276, targets B7-H3, a protein found on diffuse intrinsic pontine glioma cells and other pediatric brain tumors but only minimally present on healthy tissue, according to BioSpace. As reported by Fierce Biotech, the Series A round will fund a pivotal Phase 2 trial of BCB-276, with Seattle Children's Hospital and WRF Capital, the investment vehicle for Washington Research Foundation, joining the round alongside a private family fund. Diffuse intrinsic pontine glioma, known as DIPG, is a rare brainstem cancer that strikes 250 to 300 children in the United States each year, per Fierce Biotech, and tumors that grow at the base of the brain make surgery and existing cancer drugs unavailable options for these young patients.
A Delivery System Built to Beat the Blood-Brain Barrier
DIPG tumors are shielded by the blood-brain barrier, the biological wall that keeps most drugs, including standard intravenous CAR-T infusions used for blood cancers, from ever reaching the brainstem. BrainChild Bio's platform sidesteps that barrier entirely by delivering the modified T cells straight into the cerebrospinal fluid through an indwelling reservoir-catheter, administering up to 15 doses over 7 to 8 months without requiring patients to undergo systemic lymphodepleting chemotherapy, according to FirstWord Pharma. That repeat-dosing regimen stands in contrast to other approved CAR-T therapies, which are typically dosed only once, Fierce Biotech reports.
Company studies found that the injected cells could travel through the corpus callosum, the thick band of nerve fibers at the center of the brain, and reach tumors in the opposite hemisphere from where they were introduced, per the outlet's report. Dr. Michael Jensen, the pediatric oncologist who founded BrainChild Bio, said the cells are very good at attacking tumors from the outside in, according to Fierce Biotech. Standard radiation therapy for DIPG is considered entirely palliative, typically adding only a few months of life, the outlet notes.
Underlying Trial Data and Regulatory Pathway
The company's approach builds on results from the earlier BrainChild-03 Phase 1 trial, published in Nature Medicine, in which 21 pediatric DIPG patients receiving repetitive intracerebroventricular B7-H3 CAR-T doses showed a median overall survival of 19.8 months from diagnosis, according to research indexed on PubMed. That compares to a roughly 11-month median survival with standard focal radiation and just 3 months without any treatment, with historical registries showing a 5-year survival rate under 2 percent, per data cited in the National Institutes of Health's PMC database.
Because a control arm without CAR-T cells would be expected to result in 100 percent of enrolled children dying, the FDA allowed BrainChild Bio to compare BCB-276's results against natural-history data instead of running a placebo-controlled trial, Fierce Biotech reports. Jensen said the FDA's support for that natural-history comparison strategy is critically important for this patient population, according to the outlet. The agency granted BCB-276 Breakthrough Therapy designation in April 2025, Regenerative Medicine Advanced Therapy designation the following month, and Fast Track designation after a Type B meeting where regulators agreed to the single-arm pivotal design, according to CGTlive.
Trial Sites and a Broader Pipeline
The pivotal trial, named ILLUMINATE, is an open-label, single-arm registrational study enrolling 75 patients across six U.S. pediatric oncology centers in Seattle, Chicago, Atlanta, Philadelphia, Los Angeles and Columbus, Ohio, with topline data expected in 2028, according to Endpoints News. Endpoints News also reports that BrainChild Bio secured a manufacturing partnership in 2025 with contract development organization OmniaBio to establish commercial-scale production for the patient-derived cell therapy.
BrainChild Bio is also developing a second program, BCB-214, a triple-targeting CAR-T therapy aimed at B7-H3, EGFR and IL13Rα2 designed to combat tumor heterogeneity, according to Scrip. The company plans to launch a Phase 1 glioblastoma trial next year, with those engineered cells intended to attack glioblastoma, an aggressive brain cancer that includes adult patients and accounts for roughly 15,000 new U.S. cases annually, Fierce Biotech reports — a market far larger than the rare pediatric cancers the company was built to treat. Fierce Biotech notes that the first solid-tumor CAR-T therapy overall was approved in China, developed by Shanghai-based CARsgen Therapeutics.
A Funding Model Built for a Tiny Patient Population
BrainChild Bio was spun out of Seattle Children's Hospital in December 2023 to commercialize Jensen's research, with the hospital serving as the startup's sole financial backer for two years before co-investing in the Series A itself, according to Endpoints News. Steven Brugger described the investor syndicate as unique and committed, and characterized BrainChild Bio's overall strategy as kids first, but not kids only, per Fierce Biotech.
Venture capital investment in pediatric oncology startups remains extraordinarily rare because the patient populations are so small, forcing companies like BrainChild Bio to rely on disease-focused family offices, academic venture funds and charitable foundations rather than traditional institutional investors, Endpoints News reports. Brain tumors remain the leading cause of cancer death in children, according to Fierce Biotech, underscoring why regulators and a small circle of dedicated funders moved to accelerate a therapy for a disease that has never had an approved drug of its own.
